ECSP19085426A - Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica - Google Patents
Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémicaInfo
- Publication number
- ECSP19085426A ECSP19085426A ECSENADI201985426A ECDI201985426A ECSP19085426A EC SP19085426 A ECSP19085426 A EC SP19085426A EC SENADI201985426 A ECSENADI201985426 A EC SENADI201985426A EC DI201985426 A ECDI201985426 A EC DI201985426A EC SP19085426 A ECSP19085426 A EC SP19085426A
- Authority
- EC
- Ecuador
- Prior art keywords
- dimiracetam
- proportion
- racemic
- compositions including
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invención se refiere a una composición de enantiómeros de 3,6,7,7a-tetrahidro-1H-pirrolo[1,5-a]imidazol-2,5-diona y solvatos o co-cristales farmacéuticamente aceptables del mismo en una cierta proporción, una composición farmacéutica que comprende dicha composición, su uso como un medicamento y el uso de las composiciones inventivas o composiciones farmacéuticas en el tratamiento y/o prevención de una enfermedad o trastorno seleccionado generalmente y preferiblemente de neuropatía sensorial periférica, preferiblemente dolor neuropático periférico; convulsiones; depresión; o deterioro cognitivo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17173760 | 2017-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19085426A true ECSP19085426A (es) | 2020-05-29 |
Family
ID=59053899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201985426A ECSP19085426A (es) | 2017-05-31 | 2019-11-29 | Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica |
Country Status (32)
Country | Link |
---|---|
US (2) | US10738054B2 (es) |
EP (2) | EP3534898B1 (es) |
JP (2) | JP6810983B2 (es) |
KR (1) | KR102269493B1 (es) |
CN (1) | CN110719779B (es) |
AU (1) | AU2018276382B2 (es) |
BR (1) | BR112019025006A2 (es) |
CA (1) | CA3061274C (es) |
CL (1) | CL2019003503A1 (es) |
CO (1) | CO2019013212A2 (es) |
CY (1) | CY1123386T1 (es) |
DK (1) | DK3534898T3 (es) |
EA (1) | EA201992817A1 (es) |
EC (1) | ECSP19085426A (es) |
ES (1) | ES2825498T3 (es) |
GE (1) | GEP20227336B (es) |
HR (1) | HRP20201608T1 (es) |
HU (1) | HUE050981T2 (es) |
IL (1) | IL270833B (es) |
JO (1) | JOP20190251A1 (es) |
LT (1) | LT3534898T (es) |
MX (1) | MX2019013897A (es) |
NI (1) | NI201900122A (es) |
PE (1) | PE20200699A1 (es) |
PH (1) | PH12019502580A1 (es) |
PT (1) | PT3534898T (es) |
RS (1) | RS60957B1 (es) |
SG (1) | SG11201909720SA (es) |
SI (1) | SI3534898T1 (es) |
UA (1) | UA125703C2 (es) |
WO (1) | WO2018219977A1 (es) |
ZA (1) | ZA201906863B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190251A1 (ar) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
BR112021010739A2 (pt) * | 2018-12-04 | 2021-08-24 | Metys Pharmaceuticals AG | Composições sinérgicas compreendendo (r)-(2-(2-oxopirrolidina-1-il)butanamida e (s)-2-(2-oxopirrolidina-1-il)butanamida) em uma proporção não racêmica |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200406A (en) | 1988-02-08 | 1993-04-06 | I.S.F. Societa Per Azioni | Pharmaceutically useful 2,5-dioxo-1H-octahydroimidazo[1,2-A]azepines |
IT1233860B (it) | 1988-02-08 | 1992-04-21 | Isf Spa | Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa |
GB9123641D0 (en) * | 1991-11-07 | 1992-01-02 | Isf Spa | Process |
CN1329590A (zh) * | 1998-12-02 | 2002-01-02 | 达尔文发现有限公司 | 治疗产品及其应用 |
EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
ITMI20030573A1 (it) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
US20100048605A1 (en) * | 2006-12-11 | 2010-02-25 | University Of Kentucky Research Foundation | Synergistic effects of combinations of nornicotine and opioids for the treatment of pain |
AU2012201853B2 (en) * | 2007-04-16 | 2013-06-27 | Neurotune Ag | Use of dimiracetam in the treatment of chronic pain |
ITMI20070770A1 (it) * | 2007-04-16 | 2008-10-17 | Brane Discovery S R L | Impiego di dimiracetam nel trattamento del dolore cronico |
EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
PL2098526T3 (pl) | 2008-02-22 | 2014-06-30 | Neurotune Ag | Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu |
US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
JP5919270B2 (ja) | 2010-07-26 | 2016-05-18 | ニューロチューン・アクチエンゲゼルシャフト | ジミラセタムの製造方法 |
RU2013141926A (ru) | 2010-10-29 | 2015-03-20 | Нойротуне Аг | Терапевтическое применение димирацетама для предотвращения ладонно-подошвенного синдрома, вызываемого сорафенибом |
WO2015010217A1 (en) | 2013-07-24 | 2015-01-29 | Neurotune Ag | Dimiracetam in the treatment of depression |
JOP20190251A1 (ar) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
-
2017
- 2017-06-16 JO JOP/2019/0251A patent/JOP20190251A1/ar unknown
-
2018
- 2018-05-30 EA EA201992817A patent/EA201992817A1/ru unknown
- 2018-05-30 ES ES18728356T patent/ES2825498T3/es active Active
- 2018-05-30 LT LTEP18728356.9T patent/LT3534898T/lt unknown
- 2018-05-30 GE GEAP201815251A patent/GEP20227336B/en unknown
- 2018-05-30 PE PE2019002444A patent/PE20200699A1/es unknown
- 2018-05-30 RS RS20201220A patent/RS60957B1/sr unknown
- 2018-05-30 MX MX2019013897A patent/MX2019013897A/es active IP Right Grant
- 2018-05-30 HU HUE18728356A patent/HUE050981T2/hu unknown
- 2018-05-30 AU AU2018276382A patent/AU2018276382B2/en active Active
- 2018-05-30 DK DK18728356.9T patent/DK3534898T3/da active
- 2018-05-30 CA CA3061274A patent/CA3061274C/en active Active
- 2018-05-30 PT PT187283569T patent/PT3534898T/pt unknown
- 2018-05-30 EP EP18728356.9A patent/EP3534898B1/en active Active
- 2018-05-30 SI SI201830125T patent/SI3534898T1/sl unknown
- 2018-05-30 EP EP20181525.5A patent/EP3735971A1/en not_active Withdrawn
- 2018-05-30 SG SG11201909720S patent/SG11201909720SA/en unknown
- 2018-05-30 JP JP2020516950A patent/JP6810983B2/ja active Active
- 2018-05-30 KR KR1020197038320A patent/KR102269493B1/ko active IP Right Grant
- 2018-05-30 WO PCT/EP2018/064125 patent/WO2018219977A1/en unknown
- 2018-05-30 UA UAA201911923A patent/UA125703C2/uk unknown
- 2018-05-30 US US15/992,529 patent/US10738054B2/en active Active
- 2018-05-30 CN CN201880034236.3A patent/CN110719779B/zh active Active
- 2018-05-30 BR BR112019025006-9A patent/BR112019025006A2/pt not_active Application Discontinuation
-
2019
- 2019-10-17 ZA ZA2019/06863A patent/ZA201906863B/en unknown
- 2019-11-18 PH PH12019502580A patent/PH12019502580A1/en unknown
- 2019-11-21 IL IL270833A patent/IL270833B/en active IP Right Grant
- 2019-11-26 CO CONC2019/0013212A patent/CO2019013212A2/es unknown
- 2019-11-27 NI NI201900122A patent/NI201900122A/es unknown
- 2019-11-29 EC ECSENADI201985426A patent/ECSP19085426A/es unknown
- 2019-11-29 CL CL2019003503A patent/CL2019003503A1/es unknown
-
2020
- 2020-07-01 US US16/918,772 patent/US20200331919A1/en not_active Abandoned
- 2020-10-05 CY CY20201100929T patent/CY1123386T1/el unknown
- 2020-10-07 HR HRP20201608TT patent/HRP20201608T1/hr unknown
- 2020-12-07 JP JP2020202501A patent/JP7157471B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
ECSP19085426A (es) | Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica | |
CO2020001242A2 (es) | Dihidrooxadiazinonas | |
UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
MX2022002331A (es) | Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]. | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
AU2018260628A1 (en) | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | |
UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
CL2017002229A1 (es) | Inhibidores de bace1. | |
CL2019002020A1 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer. | |
BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
ECSP21040300A (es) | Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
PH12021551239A1 (en) | Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio | |
MX2020004105A (es) | Formulacion farmaceutica. | |
MX2020007627A (es) | Uso de la carrimicina o de sus ingredientes activos. | |
CO2024002715A2 (es) | Formulaciones de radiprodil | |
CL2022001015A1 (es) | Uso de compuestos de imidazopirimidina o imidazotriazina para prevención, alivio o tratamiento de trastornos cognitivos. | |
EA201600360A2 (ru) | Фармацевтические композиции на основе 9-бутиламино-3,3-диметил-3,4-дигидроакридин-1(2h)-она гидрохлорида для коррекции когнитивных и неврологических нарушений |